Phase 2 N=20 Safety & Tolerability of Berinert® (C1 Inhibitor) Therapy to Prevent Rejection
Kidney Transplantation
Primary: Post-transplant Biopsy to Identify Rejection Episodes — 2; 3 Episode of rejection
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=10 Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant
Antibody-mediated Rejection · Kidney Transplant; Complications · Transplant Glomerulopathy
Primary: Number of Participants With Donor Specific Antibody (DSA) Elimination or Reduction Based on Luminex HLA Testing — 7 Participants
Phase 3 N=36 The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation
Antibody-mediated Rejection · Hyperacute Rejection of Cardiac Transplant · Left Ventricular Dysfunction
Primary: Number of Participants of Pathologic Antibody-Mediated Rejection and Left Ventricular Dysfunction — 4 Participants
Phase 2 N=40 Belatacept Post Depletional Repopulation to Facilitate Tolerance
Organ Transplantation
Primary: Number of Patients Successfully Withdrawn From Oral Immunosuppression — 12; 7 Participants
Phase 4 N=222 Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation
Graft Rejection
Primary: Patient Survival — 109; 104 Participants
Phase 4 N=20 Mechanisms of Belatacept Effect on Alloimmunity and Antiviral Response After Kidney Transplantation (BMS IM 103-309)
Renal Transplant Rejection
Primary: Antibody and T Cell-mediated Immune Response — 17; 0; 0; 1 participants
Phase 2 N=23 Safety and Efficacy of Alemtuzumab in Pediatric Intestinal Transplantation
Evidence of Liver Transplantation · Rejection · ALEMTUZUMAB
Primary: Incidence of Post Transplant Lymphoproliferative Disorder (PTLD) — 6 participants
Phase 2 N=1 C1-Inhibitor (INH) for Refractory Antibody Mediated Renal Allograft Rejection
Antibody Mediated Rejection of Kidney Transplant
Primary: Renal Allograft Survival Measured by Severe and Refractory Antibody Mediated Renal (AMR) — 1 Participants
Phase 3 N=707 Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to Two Meningococcal Reference Vaccines in European Toddlers
Meningococcal Immunisation (Healthy Volunteers)
Primary: Percentage of Participants With Antibody Titers >=1:8 Against Meningococcal Serogroup C Measured by Serum Bactericidal Assay Using Human Complement (hSBA) Following…
Phase 2 N=12 Sirolimus and Thymoglobulin to Prevent Kidney Transplant Rejection
Kidney Failure
Primary: Serum Creatinine Concentration — 112 umol/L
Phase 2 N=31 Combination Drug Therapy Followed by Single Drug Steroid Free Therapy to Prevent Organ Rejection in Kidney Transplantation
Kidney Transplantation
Primary: The Rate of Allograft Rejection — 0; 0 participants
Phase 2 N=43 Study of Iodine-131 Anti-B1 Antibody for Patients With Non Hodgkin's Lymphoma Who Have Previously Received Rituximab
Lymphoma, Non-Hodgkin
Primary: Number of Participants (Par.) With Confirmed Response as Assessed by the Investigator — 26 participants
Phase 2 N=18 A Pilot Study to Evaluate the Use of C1 Esterase Inhibitor (Human) in Patients With Acute Antibody-Mediated Rejection
Graft Rejection
Primary: Change From Baseline in Histopathology Endpoints — -45.0; -36.1; -6.0; 12.6 scores on a scale — p=0.6498
Phase 2 N=29 An Efficacy and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant Patients
Kidney Transplant Rejection
Primary: Maximum Reduction in Donor Specific Antibodies (DSA) Level During the 5 Days Following the Start of Treatment — 94; 36 percentage of maximum DSA reduction
Phase 2 N=25 A Study of Belimumab in the Prevention of Kidney Transplant Rejection
Transplantation, Organ
Primary: Change From Baseline in naïve B Cells From Baseline to Week 24 — 4.0; -30.4 cells/mm^3